PD-L1 PET-imaging During CAR T-cell Therapy

Large B-cell Lymphoma Clinical Trial

Official title:

Programmed Death Ligand 1 (PD-L1)-PET Imaging in Patients With (Diffuse) Large B-cell Lymphoma Who Are Treated With CD19-directed CAR T-cell Therapy: a Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05404048
• Other study ID #: 202100663
• Status: Recruiting
• Phase: Phase 2
• Start date: May 18, 2022
• Est. completion date: May 2025

Study information

• Verified date: November 2023
• Source: University Medical Center Groningen
• Contact: Janneke W de Boer, MD
• Phone: +31625573522
• Email: j.w.de.boer[@]umcg.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, single-arm pilot trial designed to evaluate the expression of PD-L1 in patients with Large B-cell lymphoma (LBCL) and its role in non-responsiveness to chimeric antigen receptor (CAR) T-cell therapy in a non-invasive manner. Moreover, within this trial 89Zr-atezolizumab PET/CT imaging as a tool to distinguish lymphoma activity from a treatment-related inflammatory signal (histiocytic/sarcoid-like reaction) in patients with an end-of-treatment positive FDG PET/CT signal will be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: May 2025
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed LBCL and associated subtypes, defined by WHO 2016 classification

• Tumor lesion(s) of which a histological biopsy can safely be obtained according to Standard clinical care procedures.

• Measurable disease, as defined by Lugano criteria.

• If has history of central nervous system (CNS) disease, then must have no signs or symptoms of CNS disease, no active disease on magnetic resonance imaging (MRI) and absence of large cell lymphoma in cerebral spinal fluid (CSF) on cytospin preparation and flow cytometry, regardless of the number of white blood cells.

• If has history of cerebral vascular accident (CVA), the CVA event must be 12 months prior to apheresis and any neurological deficits must be stable.

• Signed informed consent.

• Age >18 at the time of signing informed consent.

• Life expectancy >12 weeks.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Ability to comply with the protocol.

Exclusion Criteria:

• Signs or symptoms of active infection within 2 weeks prior to 89Zr-atezolizumab injection, unless treated to resolution.

• Prior CD19-directed CAR T-cell therapy or other bi-specific antibodies targeting CD19 receptor (e.g.blinatumomab).

• History of severe allergy, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.

• Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of 89Zr-atezolizumab, or that may affect the interpretation of the results or render the patient at high risk for complications.

Related Conditions & MeSH terms

• Large B-cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell

Intervention

Other:
• 89Zr-atezolizumab PET-imaging
89Zr-atezolizumab tracer injection + PET/CT-scan

Locations

Country	Name	City	State
Netherlands	University Medical Center Groningen	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the expression of PD-L1 in normal tissue and lymphoma lesions before CAR T-cell therapy by 89Zr-atezolizumab PET/CT imaging.		2 year
Primary	To correlate the pretreatment 89Zr-atezolizumab uptake to the objective response rate to CAR T-cell therapy.		2 year
Primary	To evaluate the utility of the 89Zr-atezolizumab uptake to distinguish lymphoma activity from a treatment-related inflammatory reaction in patients with an end-of-treatment 18F-FDG-positive PET/CT signal.		2 year
Secondary	To correlate the pretreatment 89Zr-atezolizumab distribution to CAR T-cell peak expansion and persistence.		2 year
Secondary	To correlate the pretreatment 89Zr-atezolizumab uptake to CAR T-cell therapy related grade 1-5 adverse events (cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS)).		2 year
Secondary	To correlate tumor 89Zr-atezolizumab uptake with tumor and immune cell PD-L1 expression as assessed by immunohistochemistry on a fresh contemporaneous tumor biopsy.		2 year
Secondary	To compare the 89Zr-atezolizumab distribution in irradiated versus non-irradiated lymphoma lesions in patients who require radiotherapy as a bridging strategy prior to CAR T-cell infusion.		2 year
Secondary	To determine the incidence of a treatment-related inflammatory signal on 18F-FDGPET/CT scan (histiocytic/sarcoid-like reaction) after CAR T-cell therapy.		2 year